Baxter International (BAX) reported a significant net loss in Q4, with adjusted earnings per share (EPS) of $0.44, falling short of analysts' estimates of $0.54. This earnings miss occurred despite a notable 8% increase in worldwide net sales, reaching $2.97 billion. Adding to investor concerns, the medical products company provided a weak fiscal year 2026 outlook. It projected adjusted EPS for FY26 to be between $1.85 and $2.05, considerably below the Street's expectation of $2.25 per share. Following these announcements, Baxter's stock (BAX) experienced a sharp decline, tumbling 14.63% in pre-market trading. The disappointing Q4 results and subdued long-term guidance signal significant negative market sentiment for the company.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis